Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical studies with ropinirole in Parkinson's disease and RLS.

Literature DB >> 16944351

Clinical studies with ropinirole in Parkinson's disease and RLS.

Wolfgang H Jost¹, Dieter Angersbach, Olivier Rascol.

Abstract

Ropinirole is a modern dopamine agonist with a half-life of medium extent that is highly selective for D(2)-receptors. Ropinirole is an indole derivative and thus does not belong to the group of ergoline dopamine receptor agonists. Its effect has been proved in a number of controlled studies in both monotherapy and combination treatments of Parkinson's disease. We can meanwhile refer to the long-term data of studies that have been run for more than 10 years. The substance has also been approved for the management of restless legs syndrome. A long-acting formula of the substance will be available soon.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2006 PMID： 16944351 DOI： 10.1007/s00415-006-4004-4

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

28 in total

1. Equivalent doses of ropinirole and bromocriptine.

Authors: W H Jost
Journal: Eur J Neurol Date: 1999-09 Impact factor: 6.089

Review 2. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Authors: C E Clarke; K H Deane
Journal: Cochrane Database Syst Rev Date: 2001

3. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.

Authors: Richard K Bogan; June M Fry; Markus H Schmidt; Stanley W Carson; Sally Y Ritchie
Journal: Mayo Clin Proc Date: 2006-01 Impact factor: 7.616

4. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.

Authors: A Lieberman; C W Olanow; K Sethi; P Swanson; C H Waters; S Fahn; H Hurtig; M Yahr
Journal: Neurology Date: 1998-10 Impact factor: 9.910

Review 5. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.

Authors: Mahyar Etminan; Sudeep Gill; Ali Samii
Journal: Drug Saf Date: 2003 Impact factor: 5.606

6. Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome.

Authors: Eric Konofal; Isabelle Arnulf; Michel Lecendreux; Marie-Christine Mouren
Journal: Pediatr Neurol Date: 2005-05 Impact factor: 3.372

7. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.

Authors: O Rascol; D J Brooks; E R Brunt; A D Korczyn; W H Poewe; F Stocchi
Journal: Mov Disord Date: 1998-01 Impact factor: 10.338

8. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.

Authors: A D Korczyn; D J Brooks; E R Brunt; W H Poewe; O Rascol; F Stocchi
Journal: Mov Disord Date: 1998-01 Impact factor: 10.338

9. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.

Authors: E R Brunt; D J Brooks; A D Korczyn; J-L Montastruc; F Stocchi
Journal: J Neural Transm (Vienna) Date: 2002-04 Impact factor: 3.575